<- Go Home
89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Market Cap
$1.2B
Volume
1.2M
Cash and Equivalents
$315.4M
EBITDA
-$403.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.84
52 Week Low
$4.16
Dividend
N/A
Price / Book Value
1.98
Price / Earnings
-2.49
Price / Tangible Book Value
1.98
Enterprise Value
$595.9M
Enterprise Value / EBITDA
-1.48
Operating Income
-$403.3M
Return on Equity
69.30%
Return on Assets
-39.93
Cash and Short Term Investments
$638.8M
Debt
$37.6M
Equity
$605.5M
Revenue
N/A
Unlevered FCF
-$259.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium